1.FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer.
Giwon KIM ; Yeon Sil KIM ; Eun Ji HAN ; Ie Ryung YOO ; Jin Ho SONG ; Sang Nam LEE ; Jong Hoon LEE ; Byung Oak CHOI ; Hong Seok JANG ; Sei Chul YOON
Radiation Oncology Journal 2011;29(4):243-251
PURPOSE: To evaluate the prognostic value of metabolic tumor volume (MTV) and maximum standardized uptake value (SUVmax) on initial positron emission tomography-computed tomography (PET-CT) and investigate the clinical value of SUVmax for early detection of locoregional recurrent disease after postoperative radiotherapy in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: A total of 100 patients with locally advanced HNSCC received primary tumor excision and neck dissection followed by adjuvant radiotherapy with or without chemotherapy. The MTV and SUVmax were measured from primary sites and neck nodes. The prognostic value of MTV and SUVmax were assessed using initial staging PET/CT (study A). Follow-up PET/CT scan available after postoperative concurrent chemoradiotherapy or radiotherapy were evaluated for the SUVmax value and correlated with locoregional recurrence (study B). A receiver operating characteristic (ROC) curve analysis was used to define a threshold value of SUVmax with the highest accuracy for recurrent disease assessment. RESULTS: High MTV (>41 mL) is negative prognostic factor for disease free survival (p = 0.041). Postradiation SUVmax was significantly correlated with locoregional recurrence (hazard ratio, 1.812; 95% confidence interval, 1.361 to 2.413; p < 0.001). A cut-off value of 5.38 from follow-up PET/CT was identified as having maximal accuracy for detecting locoregional recurrence by ROC analysis. CONCLUSION: MTV at staging work-up was significantly associated with disease free survival. The SUVmax value from follow-up PET/CT showed high diagnostic accuracy for the detection of locoregional recurrence in postoperatively irradiated HNSCC.
Carcinoma, Squamous Cell
;
Chemoradiotherapy
;
Disease-Free Survival
;
Electrons
;
Follow-Up Studies
;
Head
;
Head and Neck Neoplasms
;
Humans
;
Neck
;
Neck Dissection
;
Positron-Emission Tomography
;
Radiotherapy, Adjuvant
;
Recurrence
;
ROC Curve
;
Tumor Burden
2.Non-Malignant 18F-FDG Uptake in the Thorax by Positron Emission Tomography Computed Tomography Fusion Imaging.
Hyun Jin PARK ; Ie Ryung YOO ; Ho Jong CHUN ; Sun Wha SONG ; Soo Ah IM ; Seog Hee PARK ; Sung Hoon KIM ; Kyo young LEE
Journal of the Korean Radiological Society 2007;57(1):43-50
Fluorine-18 2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) has been used exclusively to diagnose malignancies. However, increased FDG uptake is not always limited to malignant tissue. Many false positive findings for PET have been reported. Moreover, the use of PET/CT may allow the reassessment of previously recognized patterns of physiological bio-distribution of a tracer. In this report we demonstrate the physiological FDG uptake of normal structures in the thorax using PET/CT imaging and illustrate many benign pathological conditions with standardized uptake values greater than 2.5.
Electrons*
;
Fluorodeoxyglucose F18*
;
Positron-Emission Tomography and Computed Tomography
;
Positron-Emission Tomography*
;
Thorax*
3.Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study.
Jeong Il KIM ; Seok Hyun KIM ; Byung Seok LEE ; Heon Young LEE ; Tae Hee LEE ; Young Woo KANG ; Hyang Ie LEE ; An Na KIM ; Soon Woo NAM ; Byeong Chool PARK ; Hee Bok CHAE ; Seok Bae KIM ; Il Han SONG ; Ji Young PARK ; Hong Su KIM
The Korean Journal of Hepatology 2008;14(4):493-502
BACKGROUNDS/AIMS: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C. METHODS: Ninety-seven patients were treated with peginterferon alpha-2a (180 microgram/week, n=48) or peginterferon alpha-2b (1.5 microgram/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively. RESULTS: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peginterferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia. CONCLUSIONS: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
Adult
;
Antiviral Agents/*administration & dosage
;
Combined Modality Therapy
;
Genotype
;
Hepacivirus/drug effects/genetics
;
Hepatitis C, Chronic/diagnosis/*drug therapy
;
Humans
;
Interferon Alfa-2a/*administration & dosage
;
Interferon Alfa-2b/*administration & dosage
;
Korea
;
Middle Aged
;
Polyethylene Glycols/*administration & dosage
;
Retrospective Studies
;
Ribavirin/*administration & dosage
;
Risk Factors
4.Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B.
Hyeon Woong YANG ; Byung Seok LEE ; Tae Hee LEE ; Heon Young LEE ; Kwan Woo NAM ; Young Woo KANG ; Hee Bok CHAE ; Seok Hyun KIM ; Seok Bae KIM ; Hyang Ie LEE ; An Na KIM ; Il Han SONG ; Sae Hwan LEE ; Hong Su KIM
The Korean Journal of Internal Medicine 2010;25(4):372-376
BACKGROUND/AIMS: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naive patients with CHB living in Daejeon and Chungcheong Province, South Korea. METHODS: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months. RESULTS: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 +/- 188 IU/L, 150 +/- 138 IU/L, and 7.1 +/- 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough. CONCLUSIONS: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough.
Adult
;
Alanine Transaminase/blood
;
Antiviral Agents/*therapeutic use
;
Arabinofuranosyluracil/*analogs & derivatives/therapeutic use
;
Female
;
Hepatitis B e Antigens/blood
;
Hepatitis B, Chronic/drug therapy/virology
;
Humans
;
Male
;
Middle Aged
;
Retrospective Studies
5.Hypofractionated High-Dose Intensity-Modulated Radiotherapy (60 Gy at 2.5 Gy per Fraction) for Recurrent Renal Cell Carcinoma: A Case Report.
Jaeho CHO ; Gwi Eon KIM ; Koon Ho RHA ; Joong Bae AHN ; Chang Geol LEE ; Chang Ok SUH ; Jinsil SEONG ; Ki Chang KEUM ; Song Ie KIM ; Yoon Hee LEE
Journal of Korean Medical Science 2008;23(4):740-743
A patient with renal cell carcinoma (RCC) developed synchronous bone metastasis with metachronous relapses to the bone and renal fossa. The primary lesion was initially removed surgically, and the metastatic bone lesions and locally recurrent tumours were treated by a high-fractional dose and high-total-dose intensitymodulated radiotherapy (IMRT, 60 Gy at 2.5 Gy per fraction) without significant side effects. All the grossly relapsed tumors underwent complete remission (CR) within a short time after IMRT. To date, CR has been maintained for more than two years. This case study reports the successful treatment of radioresistant RCC using a new scheme that involves a fractionation regimen with a high precision radiotherapy.
Carcinoma, Renal Cell/pathology/*radiotherapy
;
Dose Fractionation
;
Female
;
Humans
;
Kidney Neoplasms/pathology/*radiotherapy
;
Middle Aged
;
Neoplasm Recurrence, Local/pathology/*radiotherapy
;
Radiotherapy, Intensity-Modulated